Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + trabectedin with or without carboplatin for platinum-partially sensitive recurrent ovarian cancer
2012-003866-42Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer and epithelial ovarian cancer (EOC) comparing Bevacizumab + trabectedin with Bevacizumab + trabectedin + carboplatin (2 arms). Primary endpoints: Proportion of progression-free patients at 6 months and Proportion of patients with severe toxicity at 6 months. Started Nov 2012; status: completed.
02
Drugs
bevacizumabtrabectedincarboplatin
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2012-003866-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003866-42.